ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1386

Genetic Variation and Coronary Atherosclerosis in Patients with Systemic Lupus Erythematosus

Cecilia P. Chung1, Joseph F. Solus2, Annette Oeser3, Chun Li4, Paolo Raggi5, Jeffrey R. Smith3 and C. Michael Stein6, 1Medicine, Vanderbilt University School of Medcine, Nashville, TN, 2Medicine, Vanderbilt University, Nashville, TN, 3Vanderbilt University, Nashville, TN, 4Biostatistics, Vanderbilt University, Nashville, TN, 5University of Alberta, Edmonton, AB, Canada, 6Internal Medicine and Pharmacology, Vanderbilt University, Nashville, TN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, Cardiovascular disease, gene and systemic lupus erythematosus, SNPs

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Premature coronary artery disease is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). However, this is not explained by traditional cardiovascular risk factors or markers of inflammation. Little is known about the contribution of genetic variation to atherosclerosis in this patient population. Therefore, we examined the hypothesis that, in patients with SLE, candidate gene polymorphisms were associated with the presence of coronary atherosclerosis.

Methods: One hundred and twenty five patients with SLE, enrolled in an ongoing study to evaluate the prevalence and associated risk factors of coronary atherosclerosis in SLE, were studied. Patients fulfilled the 1997 American College of Rheumatology classification criteria for SLE and were 18 years or older. Coronary artery calcium (CAC), a non-invasive measurement of coronary atherosclerosis, was measured by electron beam computed tomography. Using the Illumina Goldengate platform, we determined the genotype of 714 single-nucleotide polymorphisms (SNPs) in 176 selected candidate genes. Candidate genes were selected because of their relevance to autoimmune or cardiovascular risk. The associations between the presence of CAC and individual SNPs were assessed with logistic regression, adjusted for age, gender, and race. To account for multiple comparisons, a false discovery rate (FDR) threshold of 20% was specified.

Results: Patients with SLE were 41±12 years old, 91% were women and 64% were Caucasian. The presence of CAC was detected in 33 patients (26%). After adjustment for age, race, and sex, associations were detected for CSF1, ADIPOQ, REST, VCAM1, MIF, TNFSF4, INS, IRF5, TH and HMOX1 (Table). However, none of these associations remained significant after FDR correction.

Table: Genetic Association with Coronary Atherosclerosis in Patients with SLE

SNP

Gene

Major, minor allele

Minor allele frequency

Odds ratio* (95% CI)

p-value

rs333947

CSF1

G,A

0.18

4.71 (1.93-11.53)

0.001

rs7649121

ADIPOQ

A,T

0.20

0.05 (0.01-0.30)

0.001

rs1862513

REST

C,G

0.31

2.94 (1.47-5.93)

0.002

rs3917009

VCAM1

C,T

0.07

3.75 (1.53-9.22)

0.004

rs875643

MIF

G,A

0.41

0.36 (0.17-0.74)

0.005

rs333970

CSF1

C,A

0.45

0.39 (0.20-0.77)

0.006

rs738806

MIF

A,G

0.25

3.24 (1.41-7.45)

0.006

rs34124816

REST

A,C

0.06

6.69 (1.51-29.72)

0.012

rs3850641

TNFSF4

A,G

0.14

3.15 (1.28-7.78)

0.013

rs3842748

INS

C,G

0.29

0.35 (0.15-0.80)

0.013

rs3745369

REST

G,C

0.41

2.49 (1.20-5.15)

0.014

rs1874328

IRF5

A,G

0.39

0.38 (0.17-0.83)

0.015

rs2070762

TH

A,G

0.44

2.43 (1.18-4.98)

0.015

rs333968

CSF1

C,T

0.26

0.41 (0.19-0.88)

0.022

rs11912889

HMOX1

G,A

0.15

0.32 (0.12-0.85)

0.022

rs3093037

CSF1

C,T

0.10

0.21 (0.06-0.81)

0.024

* Odds ratios for the comparison between minor and major allele.

Conclusion: Our results suggest that polymorphisms of genes coding CSF-1, adiponectin, resistin, VCAM-1, MIF, TNFSF-4, insulin, IRF-5, TH, and HMOX-1 may be associated with the presence of coronary atherosclerosis in patients with SLE. Studies in additional cohorts will be informative.


Disclosure:

C. P. Chung,
None;

J. F. Solus,
None;

A. Oeser,
None;

C. Li,
None;

P. Raggi,
None;

J. R. Smith,
None;

C. M. Stein,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-variation-and-coronary-atherosclerosis-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology